Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I trial evaluating genetically modified autologous T cells (ACTengine IMA201) expressing a T-cell receptor recognizing a cancer/germline antigen in patients with squamous NSCLC or HNSCC.
Authors
George R. Blumenschein
The University of Texas MD Anderson Cancer Center, Houston, TX
George R. Blumenschein, Agathe Bourgogne, Carsten Reinhardt, Hong Ma, Steffen Walter, Toni Weinschenk, Partow Kebriaei, Patrick Hwu, Harpreet Singh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses
Sub Track
Cell Therapies
Clinical Trial Registration Number
NCT03247309
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr TPS78)
DOI
10.1200/JCO.2018.36.5_suppl.TPS78
Abstract #
TPS78
Poster Bd #
M9
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.
First Author: Maria Pia Morelli
Poster
2023 ASCO Annual Meeting
Product characteristics and clinical trial design for T-Plex: Multiplexed, enhanced T cell receptor engineered T cell therapy for solid tumors.
First Author: Shrikanta Chattopadhyay
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
First Author: Christine H. Chung
Poster
2023 ASCO Annual Meeting
Role of HLA class-I antigen peptide loading complex components in immune evasion and treatment sensitivity in human lung cancer.
First Author: Adrien Costantini